Thursday, October 21, 2010

8:00 am

Welcome
Mort Coleman, MD

MYELOMA SESSION

8:10 am

Introduction to Myeloma Session
Ruben Niesvizky, MD

Session I: From Bench to Bedside

Moderator: Tomer Mark, MD

8:15 am

Evidence in favor of a myeloma stem cell
William Matsui, MD

8:40 am

Targeting the cell cycle
Selina Chen-Kiang, PhD

9:00 am

Staging, risk stratification and response evaluation: Do they change our treatment approach and impact prognosis?
Angela Dispenzieri, MD

9:20 am

Panel discussion

9:30 am

Coffee break

Session II: Myeloma Treatment

Moderator: Ruben Niesvizky, MD

9:50 am

What is the best first-line treatment for transplant-eligible patients?
Jean-Luc Harousseau, MD

10:10 am

What is the best first-line treatment for transplant-ineligible patients?
Antonio Palumbo, MD

10:30 am

What is the best treatment for relapsed patients?
Paul G. Richardson, MD

10:50 am

Extramedullary disease: A fatal condition or is there hope for an effective therapy?
Joan Bladé, MD

11:10 am

Panel discussion

11:30 am

Lunch symposium:
Optimizing clinical outcomes in hematological malignancies
Supported by Millennium Pharmaceuticals, Inc.

Session III: Special Considerations in Myeloma

Moderator: Sundar Jagannath, MD

1:30 pm

Renal insufficiency: Cause and impact on treatment selection
Sundar Jagannath, MD

1:45 pm

Osteonecrosis of the jaw: Prevention and treatment
Ashraf Badros, MD

2:00 pm

Vertebral compression fractures: Current role of kyphoplasty for improvement of pain and quality of life
Jeffrey A. Zonder, MD

2:15 pm

Thrombogenesis – causes and prevention
Antonio Palumbo, MD

2:30 pm

Panel discussion

Session IV: Special Lectures

Moderator: Morton Coleman, MD

2:35 pm

Presentation of the best Myeloma abstract Zoledronic acid (ZOL) reduces skeletal-related event (SRE) risk and increases progression-free survival (PFS) and overall survival (OS) versus clodronate in multiple myeloma (MM): MRG Myeloma lX Trial
Gareth Morgan, MD

2:45 pm

The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Presenter: Paul Richardson, MD
Recipient: Kenneth C. Anderson, MD

2:55 pm

Going for the cure or is making myeloma a chronic disease good enough?
Kenneth C. Anderson, MD

3:20 pm

Coffee break

Session V: Transplantation

Moderator: Tsiporah Shore, MD

3:40 pm

When should a transplant be performed? As initial treatment or at relapse?
Jean-Luc Harousseau, MD

4:00 pm

Goldie-Coldman/Norton-Simon hypotheses: The embodiment in Total Therapy?
Bart Barlogie, MD, PhD

4:20 pm

Allogeneic transplantation
Sergio Giralt, MD

4:40 pm

Panel discussion

4:50 pm

Adjourn